Alpha DNA Investment Management LLC Sells 3,760 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)

Alpha DNA Investment Management LLC cut its holdings in AnaptysBio, Inc. (NASDAQ:ANAB) by 23.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,160 shares of the biotechnology company’s stock after selling 3,760 shares during the period. Alpha DNA Investment Management LLC’s holdings in AnaptysBio were worth $407,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Frazier Life Sciences Management L.P. grew its holdings in AnaptysBio by 140.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock valued at $54,270,000 after purchasing an additional 1,265,891 shares during the period. Jennison Associates LLC bought a new position in AnaptysBio during the third quarter valued at $8,874,000. Victory Capital Management Inc. lifted its position in shares of AnaptysBio by 677.9% during the third quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock worth $7,948,000 after acquiring an additional 206,750 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of AnaptysBio by 55.1% during the third quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock worth $15,927,000 after acquiring an additional 168,813 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of AnaptysBio during the second quarter worth $1,360,000.

AnaptysBio Stock Performance

ANAB stock opened at $22.27 on Monday. AnaptysBio, Inc. has a 52-week low of $13.36 and a 52-week high of $41.31. The firm has a market capitalization of $677.68 million, a price-to-earnings ratio of -3.66 and a beta of -0.24. The firm has a 50 day moving average price of $29.42 and a 200-day moving average price of $29.74.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The business had revenue of $30.02 million during the quarter, compared to the consensus estimate of $7.92 million. As a group, sell-side analysts forecast that AnaptysBio, Inc. will post -6.02 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ANAB has been the topic of a number of recent analyst reports. Wedbush reiterated an “outperform” rating and issued a $42.00 price objective on shares of AnaptysBio in a research report on Thursday, November 14th. Guggenheim increased their price objective on AnaptysBio from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Truist Financial increased their price objective on AnaptysBio from $20.00 to $30.00 and gave the stock a “hold” rating in a research report on Thursday, August 15th. JPMorgan Chase & Co. lowered their price target on AnaptysBio from $75.00 to $66.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 12th. Finally, UBS Group raised their price target on AnaptysBio from $23.00 to $33.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $54.64.

Insider Buying and Selling

In other news, CFO Dennis Mulroy sold 12,220 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $39.91, for a total transaction of $487,700.20. Following the sale, the chief financial officer now directly owns 4,744 shares in the company, valued at approximately $189,333.04. This represents a 72.03 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Paul F. Lizzul sold 1,500 shares of the company’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $38.67, for a total transaction of $58,005.00. Following the transaction, the insider now owns 15,398 shares in the company, valued at $595,440.66. The trade was a 8.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 22,440 shares of company stock valued at $892,936. Company insiders own 33.70% of the company’s stock.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.